Moleculin Biotech Inc (NASDAQ:MBRX)
Moleculin Biotech Inc (NASDAQ:MBRX) announced entering into an agreement with a physician at the Mayo Clinic to perform additional research on Moleculin’s WP1066 molecule for the possible treatment of a rare form of pediatric brain tumor. Moleculin Biotech is a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates.
Mayo Clinic physician-scientists requested, and Moleculin Biotech Inc (NASDAQ:MBRX) agreed, to supply them with WP1066 for preclinical testing for the potential treatment of pediatric Diffuse Intrinsic Pontine Gliomas (DIPG), a rare and very aggressive form of brain tumor.
Mayo Clinic studies have suggested that DIPG may be particularly sensitive to the inhibition of the activated form of a cell-signaling protein called STAT3, a primary target of WP1066, and their preliminary studies have demonstrated significant anti-tumor activity of WP1066 in DIPG in vitro and in vivo tumor models.
In a statement, Moleculin Biotech Inc (NASDAQ:MBRX) Chairman and CEO, Walter Klemp, said they are thrilled to work with The Mayo Clinic in exploring the treatment potential of WP1066in in treating DIPG. He added that this should make it easier to secure an IND to study WP1066 for the treatment of adult brain tumors.
In other news, Moleculin Biotech Inc (NASDAQ:MBRX) has announced the discovery of a metabolic inhibitor with the potential to treat pancreatic cancer. Klemp announced that the company has received a lot of attention from the scientific and medical community following the company’s glucose decoy technology as a potential means of killing tumors by exploiting their hyper-dependence on glycolysis for energy production. He added that during the pre-clinical testing, the company’s WP1234 has shown improved drug characteristics compared to WP1122 and greater ability to kill pancreatic cancer cell lines when compared with traditional inhibitors of glycolysis. Klemp said that the discovery makes WP1234 a promising solution to kill pancreatic cancer which is known to survive in reduced oxygen environment.
According to Mr. Klemp, any small gain made in treating pancreatic cancer will make a significant gain in the medical field owing to the fact that the disease is largely regarded as untreatable. WP1234 works by improving on known inhibitors for glycolysis by increasing drug circulation time, which in turn increases the potential for drug uptake by destruction of tumor cells. Mr. Klemp said the discovery is a result of his company’s collaboration with M.D. Anderson Cancer Center.
During the Wednesday session, the stock of Moleculin Biotech Inc (NASDAQ:MBRX) reported a +17.31% or +$0.021 to close the session at $0.145.
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
Don’t miss out! Stay informed on $MBRX and receive breaking news on other hot stocks by signing up for our free newsletter!
About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.